MapLight Therapeutics, Inc.

Signal Note: Baker Bros. Initiates Position in MapLight Therapeutics (MPLT)

Note: The reported position value of ~$6.4B appears to be a data error — likely reflecting an incorrect price or share count, as MPLT's entire market cap is a fraction of that figure. The actual position of ~364,705 shares is more consistent with a modest, early-stage stake.

Baker Bros. initiating any new position in a micro-cap is notable given their concentrated, high-conviction style and deep biotech diligence capabilities. MapLight's lead asset, ML-007, is a novel biased agonist targeting the 5-HT2A receptor pathway for neuropsychiatric indications, positioning it in the competitive but high-value psychedelic-adjacent/neuropsychiatry space. This entry likely reflects conviction ahead of upcoming clinical data catalysts from early-stage

Signal Note: OrbiMed Initiates MapLight Position

OrbiMed's new $952K stake in MPLT signals conviction in the company's clinical pipeline, likely centered on ML402 for wet AMD, which entered Phase 2b dosing in 2H24. The entry by a top-tier healthcare allocator with deep clinical expertise suggests confidence in MapLight's retinal gene therapy platform, though the position size is modest relative to OrbiMed's typical checks, implying either a staged entry or selective thesis.